Category: Research/Reports

Economists Say 340B Hospital and Grantee Entities Use Contract Pharmacy for Different Reasons

In Research/ReportsMarch 15, 2022454 Views

A new study finds that contract pharmacy growth patterns differ between 340B hospital and non-hospital entities.

Contract pharmacy growth patterns differ between 340B hospital and non-hospital entities, suggesting they may use 340B differently and should be subject to different 340B rules, new research concludes.

Please Login or Become a Paid Subscriber to

…

New JAMA Study Casts Doubt on CMS Reason for Cutting Hospitals’ Medicare Part B Payments for 340B Drugs

In Research/ReportsFebruary 25, 2022300 Views

Tom Mirga

New research “raises doubt” about a major CMS reason for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third.

New research published in JAMA Network Open “raises doubt” about a major U.S. Centers for Medicare & Medicaid Services (CMS) justification for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third, the study’s

…

Democratic Senator’s Illness Stalls Action on Drug Pricing Indefinitely

In Federal, Legislative, Non-Governmental, Research/ReportsFebruary 10, 2022202 Views

Tom Mirga and Ron Shinkman

Sen. Ben Ray Lujan's (D-N.M.) recent stroke and absence makes it even less likely that Congress will pass Democratic drug pricing legislation any time soon.

Prospects for passage of Democratic drug pricing legislation as part of the Build Back Better (BBB) Act dimmed again last week with news that Sen. Ben Ray Lujan (D-N.M.) had a stroke on Jan 27.

Please

…

ICER Says Four Drugs Are Cost-Effective in Keeping COVID-19 Patients Out of Hospitals

In Non-Governmental, Research/ReportsFebruary 8, 2022258 Views

Ron Shinkman

The Institute for Clinical and Economic Review has tentatively concluded that four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients.

The Institute for Clinical and Economic Review (ICER) has issued a draft report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients.

Please Login or Become a Paid Subscriber to

…

Hospitals Taking Heavy Losses Due to Drug Company Limits on 340B Pricing, Survey Says

In Pharma Industry, Research/Reports, Trade AssociationJanuary 27, 2022323 Views

Tom Mirga

340B Health says a new survey of its members shows 340B hospitals “are losing significant resources” due to drug companies’ conditions on 340B pricing when covered entities use contract pharmacies.

340B hospitals “are losing significant resources” due to drug companies’ conditions on 340B pricing when covered entities use contract pharmacies, according to a new survey from hospital group 340B Health.

Please Login or Become a Paid

…

PhRMA Says More than Half of Pharmacy and Provider Profits on Brand Drug Sales Come Through 340B

In Research/Reports, Trade AssociationJanuary 11, 2022706 Views

Tom Mirga

PhRMA says 52% of U.S. pharmacies and health care providers profits' from reimbursement for administering brand-name prescription drugs now comes through participation in the 340B program. The AHA calls the finding an example of drug companies deflecting attention away from the high prices they set.

More than half (52%) of the $81 billion that U.S. pharmacies and health care providers collected in 2020 in reimbursement from payers for brand-name prescription drugs came through pharmacy and provider participation in the 340B program, up from 14% of

…

Is There a New 340B Stakeholder Group for Pharma Companies?

In Pharma Industry, Research/ReportsDecember 21, 2021370 Views

Tom Mirga

A new infographic by a drug industry consultant indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.

A new two-pager about the 340B program by drug industry consultant Berkeley Research Group (BRG) indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.

Please Login or Become a

…

U.S. Retail Drug Spending Hit $348.4 Billion in 2020 but Overall Prices Fell 0.1%

In Federal, Research/ReportsDecember 16, 2021279 Views

Tom Mirga

U.S. retail prescription drug spending hit $348.4 billion in 2020 but overall prices declined slightly, a new federal report shows.

U.S. retail prescription drug spending hit $348.4 billion in 2020, constituting 8% of total health care expenditures, a new federal report shows.

Please Login or Become a Paid Subscriber to View this Content

…

Drug Makers May Be Getting Orphan Drug Designations to Exploit 340B Orphan Drug Exclusion, HHS OIG Tells Congress

In Federal, Research/ReportsDecember 9, 2021450 Views

Tom Mirga

The 340B orphan drug exclusion may give drug makers a strong incentive to get an orphan designation for their drugs prescribed primarily for common diseases or conditions, a federal watchdog agency reminded Congress this month.

The ban on 340B pricing on orphan drugs for over 1,000 hospitals may give companies that make drugs used primarily for common diseases or conditions a strong financial incentive to get an orphan designation for those drugs, a federal watchdog

…

AIR340B Releases Study Criticizing DSH Hospital Commitment to the Underserved

In Pharma Industry, Research/ReportsNovember 23, 2021229 Views

Tom Mirga

AIR340B has released a new report saying "only true safety-net facilities" should be eligible for 340B discounts.

Drug distributor AmerisourceBergen’s business consulting unit Xcenda has written an issue brief for drug industry-led group AIR340B saying Congress and the executive branch should revise 340B eligibility standards to keep 340B “from being used solely as a profit center for

…